INKT News and Press, MiNK Therapeutics Inc. From 06/23/22

iNKT cells have unique properties that could be therapeutic. MiNK Therapeutics has shown it can both manufacture and engineer iNKT cells. Preliminary data expected before year-end could push the stock price substantially higher. For further details see: MiNK Therapeutics...

Gainers: Electric Last Mile Solutions (ELMS) +195%. Advent Technologies Holdings (ADN) +185%. Sidus Space (SIDU) +60%. Pennsylvania Real Estate Investment (PEI) +39%. Vivakor (VIVK) +32%. Akero (AKRO) +24%. Revlon (REV) +23%. Zhong Yang Financial Group (TOP) +22%. Decisionpoint Systems (DPSI)...

NEW YORK, May 25, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-me...

MiNK Therapeutics press release (NASDAQ:INKT): Q1 GAAP EPS of -$0.23. Cash balance of $34.7 million as compared to $38.9 million at December 31, 2021. For further details see: MiNK Therapeutics GAAP EPS of -$0.23

Clinical updates from solid tumor cancers and ARDS with allo-agenT-797 are on track for 2H 2022 GMP manufacturing launch in 1H 2022 with target 10,000 doses/yr BCMA-CAR-iNKT and stromal-CAR-iNKT preclinical results 2H 2022 Ended First Quarter with $34.7M in cash with a project...

NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-...

Gainers: Lixte Biotechnology Holdings (LIXT) +205%. PolarityTE (PTE) +96%. Biodesix (BDSX) +29%. MiNK Therapeutics (INKT) +27%. Enservco (ENSV) +25%. Actinium Pharmaceuticals (ATNM) +21%. Compass Therapeutics (CMPX) +21%. Sunshine Biopharma (SBFM) +22%. Singularity Future Technology (SGLY) +2...

Gainers: Momentus (MNTS) +49%. Trevi Therapeutics (TRVI) +49%. Sunshine Biopharma (SBFM) +34%. Werewolf Therapeutics (HOWL) +30%. System1 (SST) +27%. AppTech Payments (APCX) +22%. MiNK Therapeutics (INKT) +21%. Ikena Oncology (IKNA) +19%. Sprinklr (CXM) +18%. PhaseBio Pharmaceuticals (PHAS) +...

MiNK Therapeutics press release (NASDAQ:INKT): Q4 GAAP EPS of -$0.18 beats by $0.23. Cash balance of is $39M. “We have advanced our allo-iNKT program with multiple clinical programs in solid tumor cancers, multiple myeloma, and a variant agnostic therapy in severe respiratory distress ...

AgenT-797 (Allo-iNKTs) +/- anti-PD-1 clinical trial underway in solid tumor cancers Benefit in severe COVID-19 ARDS shows 75% survival rate in patients treated with Allo-iNKTs AgenT-797 treatment with no lymphodepletion shows no cytokine release syndrome or neurotoxicity 202...